BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today announces its results for the first half of 2023 and released an update on its development. Pier Vincenzo Piazza, CEO of Aelis Farma, said: “We are very pleased with the progress made over the first six months of 2023. Thanks to the efficiency, motivation, and commi
About Business Wire
